Luke M Beshar - Net Worth and Insider Trading
Luke M Beshar Net Worth
The estimated net worth of Luke M Beshar is at least $320,760 dollars as of 2023-10-03. Luke M Beshar is the Director of Protara Therapeutics Inc and owns about 198,000 shares of Protara Therapeutics Inc (TARA) stock worth over $320,760. Luke M Beshar is also the Director of Regenxbio Inc and owns about 0 shares of Regenxbio Inc (RGNX) stock worth over $0. Details can be seen in Luke M Beshar's Latest Holdings Summary section.
Transaction Summary of Luke M Beshar
Luke M Beshar Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Luke M Beshar owns 3 companies in total, including Protara Therapeutics Inc (TARA) , Regenxbio Inc (RGNX) , and Omega Therapeutics Inc (OMGA) .
Click here to see the complete history of Luke M Beshar’s form 4 insider trades.
Insider Ownership Summary of Luke M Beshar
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| TARA | Protara Therapeutics Inc | 2020-01-09 | director |
| RGNX | Regenxbio Inc | 2015-09-16 | director |
| OMGA | Omega Therapeutics Inc | 2021-07-29 | director |
Luke M Beshar Latest Holdings Summary
Luke M Beshar currently owns a total of 2 stocks. Among these stocks, Luke M Beshar owns 198,000 shares of Protara Therapeutics Inc (TARA) as of June 30, 2022, with a value of $320,760 and a weighting of 100%. Luke M Beshar also owns 0 shares of Regenxbio Inc (RGNX) as of November 29, 2018, with a value of $0 and a weighting of 0%.
Latest Holdings of Luke M Beshar
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TARA | Protara Therapeutics Inc | 2022-06-30 | 198,000 | 1.62 | 320,760 |
| RGNX | Regenxbio Inc | 2018-11-29 | 0 | 16.04 | 0 |
Holding Weightings of Luke M Beshar
Luke M Beshar Form 4 Trading Tracker
According to the SEC Form 4 filings, Luke M Beshar has made a total of 3 transactions in Protara Therapeutics Inc (TARA) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Protara Therapeutics Inc is the acquisition of 10,000 shares on June 30, 2022, which cost Luke M Beshar around $31,000.
According to the SEC Form 4 filings, Luke M Beshar has made a total of 3 transactions in Regenxbio Inc (RGNX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Regenxbio Inc is the sale of 12,784 shares on November 29, 2018, which brought Luke M Beshar around $830,960.
Insider Trading History of Luke M Beshar
- 1
Luke M Beshar Trading Performance
GuruFocus tracks the stock performance after each of Luke M Beshar's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Luke M Beshar is -17.58%. GuruFocus also compares Luke M Beshar's trading performance to market benchmark return within the same time period. The performance of stocks bought by Luke M Beshar within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Luke M Beshar's insider trading performs compared to the benchmark.
Performance of Luke M Beshar
Average Relative Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | 8.21 | -17.58 | -10.2 | -24.14 | ||
| Relative Return to S&P 500(%) | 1.63 | -9.52 | -7.36 | -24.86 |
Luke M Beshar Ownership Network
Ownership Network List of Luke M Beshar
Ownership Network Relation of Luke M Beshar
Luke M Beshar Owned Company Details
What does Protara Therapeutics Inc do?
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Who are the key executives at Protara Therapeutics Inc?
Luke M Beshar is the director of Protara Therapeutics Inc. Other key executives at Protara Therapeutics Inc include Chief Financial Officer Patrick Fabbio , VP & Controller Hannah Fry , and Chief Medical Officer Jathin Bandari .
Protara Therapeutics Inc (TARA) Insider Trades Summary
Over the past 18 months, Luke M Beshar made 1 insider transaction in Protara Therapeutics Inc (TARA) with a net purchase of 10,000. Other recent insider transactions involving Protara Therapeutics Inc (TARA) include a net purchase of 28,699 shares made by Opaleye Management Inc. , a net purchase of 9,065 shares made by Jesse Shefferman ,
In summary, during the past 3 months, insiders sold 0 shares of Protara Therapeutics Inc (TARA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 15,473 shares of Protara Therapeutics Inc (TARA) were sold and 63,237 shares were bought by its insiders, resulting in a net purchase of 47,764 shares.
Protara Therapeutics Inc (TARA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Protara Therapeutics Inc Insider Transactions
Luke M Beshar Mailing Address
Above is the net worth, insider trading, and ownership report for Luke M Beshar. You might contact Luke M Beshar via mailing address: 550 Hills Drive, 3rd Floor, Bedminster Nj 07921.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
